Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.

Pegu A, Borate B, Huang Y, Pauthner MG, Hessell AJ, Julg B, Doria-Rose NA, Schmidt SD, Carpp LN, Cully MD, Chen X, Shaw GM, Barouch DH, Haigwood NL, Corey L, Burton DR, Roederer M, Gilbert PB, Mascola JR, Huang Y.

Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.

PMID:
31513771
2.

Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, Cheever T, Fuller DH, Park B, Krebs SJ, Totrov M, Haigwood NL, Kong XP, Zolla-Pazner S.

Cell Rep. 2019 Jul 23;28(4):877-895.e6. doi: 10.1016/j.celrep.2019.06.074.

3.

Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology.

Bar KJ, Coronado E, Hensley-McBain T, O'Connor MA, Osborn JM, Miller C, Gott TM, Wangari S, Iwayama N, Ahrens CY, Smedley J, Moats C, Lynch RM, Haddad EK, Haigwood NL, Fuller DH, Shaw GM, Klatt NR, Manuzak JA.

J Virol. 2019 Aug 28;93(18). pii: e00372-19. doi: 10.1128/JVI.00372-19. Print 2019 Sep 15.

PMID:
31217249
4.

Human natural killer cells mediate adaptive immunity to viral antigens.

Nikzad R, Angelo LS, Aviles-Padilla K, Le DT, Singh VK, Bimler L, Vukmanovic-Stejic M, Vendrame E, Ranganath T, Simpson L, Haigwood NL, Blish CA, Akbar AN, Paust S.

Sci Immunol. 2019 May 10;4(35). pii: eaat8116. doi: 10.1126/sciimmunol.aat8116.

5.

Antibodies Tip the Balance Towards an HIV Cure.

Haigwood NL, Hessell AJ.

Trends Immunol. 2019 May;40(5):375-377. doi: 10.1016/j.it.2019.03.008.

PMID:
31030743
6.

IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Sarkar S, Piepenbrink MS, Basu M, Thakar J, Keefer MC, Hessell AJ, Haigwood NL, Kobie JJ.

Vaccine. 2019 Apr 17;37(17):2322-2330. doi: 10.1016/j.vaccine.2019.03.044. Epub 2019 Mar 27.

7.

Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.

Matchett WE, Anguiano-Zarate SS, Nehete PN, Shelton K, Nehete BP, Yang G, Dorta-Estremera S, Barnette P, Xiao P, Byrareddy SN, Villinger F, Hessell AJ, Haigwood NL, Sastry KJ, Barry MA.

J Virol. 2019 May 1;93(10). pii: e02016-18. doi: 10.1128/JVI.02016-18. Print 2019 May 15.

8.

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.

PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.

9.

Antibodies pose a double threat to HIV.

Haigwood NL.

Nature. 2018 Sep;561(7724):468-470. doi: 10.1038/d41586-018-06773-8. No abstract available.

PMID:
30258147
10.

Tribute to Bonnie Mathieson.

Haigwood N, Schultz A.

J Med Primatol. 2018 Oct;47(5):286-287. doi: 10.1111/jmp.12386. No abstract available.

PMID:
30255955
11.

Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.

Hessell AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, Cheever T, Sutton WF, Kahl C, Park B, Zolla-Pazner S, Haigwood NL.

J Virol. 2018 May 14;92(11). pii: e02198-17. doi: 10.1128/JVI.02198-17. Print 2018 Jun 1.

12.

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.

Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, Totrov M, Kong XP, Fiore-Gartland AJ, Haigwood NL, Zolla-Pazner S, Hioe CE.

Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0.

13.

Passive and active antibody studies in primates to inform HIV vaccines.

Hessell AJ, Malherbe DC, Haigwood NL.

Expert Rev Vaccines. 2018 Feb;17(2):127-144. doi: 10.1080/14760584.2018.1425619. Epub 2018 Jan 19. Review.

14.

Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques.

Burwitz BJ, Wettengel JM, Mück-Häusl MA, Ringelhan M, Ko C, Festag MM, Hammond KB, Northrup M, Bimber BN, Jacob T, Reed JS, Norris R, Park B, Moller-Tank S, Esser K, Greene JM, Wu HL, Abdulhaqq S, Webb G, Sutton WF, Klug A, Swanson T, Legasse AW, Vu TQ, Asokan A, Haigwood NL, Protzer U, Sacha JB.

Nat Commun. 2017 Dec 15;8(1):2146. doi: 10.1038/s41467-017-01953-y.

15.

Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Malherbe DC, Mendy J, Vang L, Barnette PT, Reed J, Lakhashe SK, Owuor J, Gach JS, Legasse AW, Axthelm MK, LaBranche CC, Montefiori D, Forthal DN, Park B, Wilson JM, McLinden JH, Xiang J, Stapleton JT, Sacha JB, Haynes BF, Liao HX, Ruprecht RM, Smith J, Gurwith M, Haigwood NL, Alexander J.

J Virol. 2018 Jan 2;92(2). pii: e01092-17. doi: 10.1128/JVI.01092-17. Print 2018 Jan 15.

16.

THE CRITICAL ROLE OF NONHUMAN PRIMATES IN MEDICAL RESEARCH.

Friedman H, Ator N, Haigwood N, Newsome W, Allan JS, Golos TG, Kordower JH, Shade RE, Goldberg ME, Bailey MR, Bianchi P.

Pathog Immun. 2017;2(3):352-365. doi: 10.20411/pai.v2i3.186. Epub 2017 Aug 23. No abstract available.

17.

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques.

Jaworski JP, Bryk P, Brower Z, Zheng B, Hessell AJ, Rosenberg AF, Wu TT, Sanz I, Keefer MC, Haigwood NL, Kobie JJ.

PLoS One. 2017 Feb 21;12(2):e0172524. doi: 10.1371/journal.pone.0172524. eCollection 2017.

18.

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE.

Vaccine. 2017 Mar 7;35(10):1464-1473. doi: 10.1016/j.vaccine.2016.11.107. Epub 2017 Feb 6.

19.

Use of broadly neutralizing antibodies for HIV-1 prevention.

Pegu A, Hessell AJ, Mascola JR, Haigwood NL.

Immunol Rev. 2017 Jan;275(1):296-312. doi: 10.1111/imr.12511. Review.

20.

E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells.

Trovato M, Maurano F, D'Apice L, Costa V, Sartorius R, Cuccaro F, McBurney SP, Krebs SJ, Prisco A, Ciccodicola A, Rossi M, Haigwood NL, De Berardinis P.

BMC Microbiol. 2016 Jul 16;16(1):152. doi: 10.1186/s12866-016-0772-x.

21.

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Hessell AJ, McBurney S, Pandey S, Sutton W, Liu L, Li L, Totrov M, Zolla-Pazner S, Haigwood NL, Gorny MK.

Vaccine. 2016 May 23;34(24):2713-21. doi: 10.1016/j.vaccine.2016.04.027. Epub 2016 Apr 19.

22.

Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

McBurney SP, Sunshine JE, Gabriel S, Huynh JP, Sutton WF, Fuller DH, Haigwood NL, Messer WB.

Vaccine. 2016 Jun 24;34(30):3500-7. doi: 10.1016/j.vaccine.2016.03.108. Epub 2016 Apr 13.

23.

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques.

Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, Reed J, Sutton WF, Hammond KB, Cheever TA, Barnette PT, Legasse AW, Planer S, Stanton JJ, Pegu A, Chen X, Wang K, Siess D, Burke D, Park BS, Axthelm MK, Lewis A, Hirsch VM, Graham BS, Mascola JR, Sacha JB, Haigwood NL.

Nat Med. 2016 Apr;22(4):362-8. doi: 10.1038/nm.4063. Epub 2016 Mar 21.

24.

Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.

Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.

J Immunol. 2016 Apr 1;196(7):3064-78. doi: 10.4049/jimmunol.1500527. Epub 2016 Mar 4.

25.

Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies.

Kobie JJ, Zheng B, Piepenbrink MS, Hessell AJ, Haigwood NL, Keefer MC, Sanz I.

Monoclon Antib Immunodiagn Immunother. 2015 Apr;34(2):65-72. doi: 10.1089/mab.2014.0064.

26.

Animal models in HIV-1 protection and therapy.

Hessell AJ, Haigwood NL.

Curr Opin HIV AIDS. 2015 May;10(3):170-6. doi: 10.1097/COH.0000000000000152. Review.

27.

HIV: tied down by its own receptor.

Haigwood NL.

Nature. 2015 Mar 5;519(7541):36-7. doi: 10.1038/nature14205. Epub 2015 Feb 18. No abstract available.

PMID:
25707798
28.

Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA.

Krebs SJ, McBurney SP, Kovarik DN, Waddell CD, Jaworski JP, Sutton WF, Gomes MM, Trovato M, Waagmeester G, Barnett SJ, DeBerardinis P, Haigwood NL.

PLoS One. 2014 Dec 16;9(12):e113463. doi: 10.1371/journal.pone.0113463. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0120027.

29.

Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Malherbe DC, Pissani F, Sather DN, Guo B, Pandey S, Sutton WF, Stuart AB, Robins H, Park B, Krebs SJ, Schuman JT, Kalams S, Hessell AJ, Haigwood NL.

J Virol. 2014 Nov;88(22):12949-67. doi: 10.1128/JVI.01812-14. Epub 2014 Sep 10.

30.

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L.

J Virol. 2014 Nov;88(22):12968-81. doi: 10.1128/JVI.01816-14. Epub 2014 Aug 13.

31.

Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity.

Ma Y, Tao W, Krebs SJ, Sutton WF, Haigwood NL, Gill HS.

Pharm Res. 2014 Sep;31(9):2393-403. doi: 10.1007/s11095-014-1335-1. Epub 2014 Mar 13.

32.

Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Pissani F, Malherbe DC, Schuman JT, Robins H, Park BS, Krebs SJ, Barnett SW, Haigwood NL.

Vaccine. 2014 Jan 16;32(4):507-13. doi: 10.1016/j.vaccine.2013.11.022. Epub 2013 Nov 23.

33.

HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Malherbe DC, Sanders RW, van Gils MJ, Park B, Gomes MM, Schuitemaker H, Barnett S, Haigwood NL.

PLoS One. 2013 Sep 9;8(9):e75277. doi: 10.1371/journal.pone.0075277. eCollection 2013.

34.

SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans.

Zhou Y, Bao R, Haigwood NL, Persidsky Y, Ho WZ.

Retrovirology. 2013 Aug 15;10:89. doi: 10.1186/1742-4690-10-89. Review.

35.

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal DN, Hessell AJ, Haigwood NL.

J Virol. 2013 Oct;87(19):10447-59. doi: 10.1128/JVI.00049-13. Epub 2013 Jul 24.

36.

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, Stamatatos L, Overbaugh J, Haigwood NL.

Vaccine. 2012 Aug 10;30(37):5519-26. doi: 10.1016/j.vaccine.2012.06.042. Epub 2012 Jun 27.

37.

Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Lifson JD, Haigwood NL.

Cold Spring Harb Perspect Med. 2012 Jun;2(6):a007310. doi: 10.1101/cshperspect.a007310.

38.

Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells.

Jaworski JP, Krebs SJ, Trovato M, Kovarik DN, Brower Z, Sutton WF, Waagmeester G, Sartorius R, D'Apice L, Caivano A, Doria-Rose NA, Malherbe D, Montefiori DC, Barnett S, De Berardinis P, Haigwood NL.

PLoS One. 2012;7(2):e31464. doi: 10.1371/journal.pone.0031464. Epub 2012 Feb 16.

39.

Delivery strategies for novel vaccine formulations.

Trovato M, Krebs SJ, Haigwood NL, De Berardinis P.

World J Virol. 2012 Feb 12;1(1):4-10. doi: 10.5501/wjv.v1.i1.4.

40.

Neutralizing antibodies and control of HIV: moves and countermoves.

Hessell AJ, Haigwood NL.

Curr HIV/AIDS Rep. 2012 Mar;9(1):64-72. doi: 10.1007/s11904-011-0105-5. Review.

PMID:
22203469
41.

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, Schuman JT, Kraft Z, O'Malley J, Mori M, Srivastava I, Barnett S, Stamatatos L, Haigwood NL.

J Virol. 2011 Jun;85(11):5262-74. doi: 10.1128/JVI.02419-10. Epub 2011 Mar 23.

42.

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL.

Nat Med. 2010 Oct;16(10):1117-9. doi: 10.1038/nm.2233. Epub 2010 Oct 3.

43.

HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.

Caivano A, Doria-Rose NA, Buelow B, Sartorius R, Trovato M, D'Apice L, Domingo GJ, Sutton WF, Haigwood NL, De Berardinis P.

Virology. 2010 Nov 25;407(2):296-305. doi: 10.1016/j.virol.2010.08.026. Epub 2010 Sep 20.

44.

Host factors involved in the viral replication and particle formation could give a new insight into the innate immunity and may turn out to be a good target for therapeutic intervention. Introduction.

Haigwood NL, Yamamoto N, Iwamoto A.

Vaccine. 2010 May 26;28 Suppl 2:B1. doi: 10.1016/j.vaccine.2009.12.013. No abstract available.

PMID:
20510736
45.

Update on animal models for HIV research.

Haigwood NL.

Eur J Immunol. 2009 Aug;39(8):1994-9. doi: 10.1002/eji.200939576.

46.

Blocking and tackling HIV.

Haigwood NL, Hirsch VM.

Nat Med. 2009 Aug;15(8):841-2. doi: 10.1038/nm0809-841. No abstract available.

PMID:
19661984
48.

Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination.

Farquhar C, Wamalwa D, Selig S, John-Stewart G, Mabuka J, Majiwa M, Sutton W, Haigwood N, Wariua G, Lohman-Payne B.

Pediatr Infect Dis J. 2009 Apr;28(4):295-9. doi: 10.1097/INF.0b013e3181903ed3.

49.

High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.

Ma ZM, Stone M, Piatak M Jr, Schweighardt B, Haigwood NL, Montefiori D, Lifson JD, Busch MP, Miller CJ.

J Virol. 2009 Apr;83(7):3288-97. doi: 10.1128/JVI.02423-08. Epub 2009 Jan 7.

50.

Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, Richardson B, Walker B, Haigwood NL.

J Virol. 2009 Jan;83(2):662-72. doi: 10.1128/JVI.01328-08. Epub 2008 Nov 5.

Supplemental Content

Loading ...
Support Center